Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study)

Table 4 Univariate Cox Regression for Survival

Variable		Hazard ratio	95 % CI	p-value
Age		0.99	0.97 - 1.03	0.836
Age (>60y)		0.51	0.24 - 1.11	0.089
Hepatic progression in FU (yes)		0.8	0.37 - 1.73	0.566
Systemic progression in FU (yes)		1.57	0.78 - 3.17	0.209
Under local control in FU (yes)		0.31	0.14 - 0.68	0.004
Her2 neu (pos)		1.22	0.59 - 2.53	0.588
Hormone receptor (pos)		0.96	0.41 - 2.24	0.926
Grading (1-3)		0.93	0.5 - 1.73	0.826
Other prior therapies for metastastes (yes)		1.99	0.89 - 4.43	0.094
Extrahepatic metastases (yes)		2.86	1.39 - 5.87	0.004
	bones only	3.01	1.49 - 6.08	0.002
First local treatment
	Brachytherapy (BT) or RFA	0.28	0.13 - 0.59	0.001
	Radioembolization (RE)	3.31	1.57 - 6.98	0.002
	Combination RE/BT or RE/RFA	1.14	0.40 - 3.26	0.813
Best response hepatic (OR, RECIST)		0.37	0.17 - 0.79	0.01
Best response overall (OR, RECIST)		0.15	0.07 - 0.34	< 0.001
Clinical and laboratory grade 3/4 toxicities (yes)		1.83	0.78 - 4.31	0.168
Number of liver metastases (≥ 6)		2.08	1.01 - 4.31	0.048
Maximum diameter of liver metastases (≥ 3.9 cm)		3.43	1.57 - 7.52	0.002
Liver volume (≥ 1376 mL)		2.27	1.11 - 4.64	0.024
Volume of liver metastases (≥ 27.9 mL)		4.33	1.91 - 9.79	< 0.001
Tumor load (≥ 2 %)		5.6	2.37 - 13.23	< 0.001
Lines of chemotherapy (≥ 3)		3.17	1.55 - 6.49	0.002
CA 15-3 (≥ 62.6U/mL)		2.42	1.10 - 5.36	0.029
CEA (≥ 6.2U/mL)		3.36	1.58 - 7.15	0.002
Time from first diagnosis to liver metastases (≥ 2y)		0.79	0.40 - 1.56	0.492
Concomitant or subsequent therapies for breast cancer metastases (yes)		0.43	0.16 - 1.16	0.094

Possible factors influencing survival were included in a univariate Cox model. Continuous variables were dichotomized according to a ROC analysis (see Additional file 1: Table S1)

ISSN: 1471-2407